NO993866D0 - Legemiddel mot lymfocytiske tumorer - Google Patents

Legemiddel mot lymfocytiske tumorer

Info

Publication number
NO993866D0
NO993866D0 NO993866A NO993866A NO993866D0 NO 993866 D0 NO993866 D0 NO 993866D0 NO 993866 A NO993866 A NO 993866A NO 993866 A NO993866 A NO 993866A NO 993866 D0 NO993866 D0 NO 993866D0
Authority
NO
Norway
Prior art keywords
medication
lymphocytic tumors
tumors
lymphocytic
seq
Prior art date
Application number
NO993866A
Other languages
English (en)
Other versions
NO993866L (no
Inventor
Yasuo Koshihara
Yasushi Yoshimura
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO993866D0 publication Critical patent/NO993866D0/no
Publication of NO993866L publication Critical patent/NO993866L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NO993866A 1997-02-12 1999-08-11 Legemiddel mot lymfatiske tumorer NO993866L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4141097 1997-02-12
PCT/JP1998/000568 WO1998035698A1 (fr) 1997-02-12 1998-02-12 Remedes contre les tumeurs lymphocitaires

Publications (2)

Publication Number Publication Date
NO993866D0 true NO993866D0 (no) 1999-08-11
NO993866L NO993866L (no) 1999-10-11

Family

ID=12607597

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993866A NO993866L (no) 1997-02-12 1999-08-11 Legemiddel mot lymfatiske tumorer

Country Status (20)

Country Link
US (2) US6503510B2 (no)
EP (1) EP0997152B1 (no)
KR (2) KR100655979B1 (no)
CN (1) CN1191855C (no)
AT (1) ATE297219T1 (no)
AU (1) AU724133B2 (no)
BR (1) BR9811094A (no)
CA (1) CA2280875C (no)
DE (1) DE69830492T2 (no)
ES (1) ES2241114T3 (no)
HK (1) HK1026368A1 (no)
HU (1) HUP0001136A3 (no)
IL (1) IL131381A0 (no)
NO (1) NO993866L (no)
PL (1) PL190065B1 (no)
RU (1) RU2177805C2 (no)
SK (1) SK110099A3 (no)
TR (1) TR199901949T2 (no)
UA (1) UA65561C2 (no)
WO (1) WO1998035698A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA948016B (en) * 1993-10-15 1995-05-31 Toshio Hirano A membrane protein polypeptide having pre-B cell crowth-supporting ability and a gene thereof
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
EP1757941B1 (en) * 1998-02-25 2010-03-31 Chugai Seiyaku Kabushiki Kaisha Method for immunochemically assaying anti-hm1.24 antibody
CA2382587A1 (en) 1999-08-23 2001-03-01 Chugai Seiyaku Kabushiki Kaisha Hm1.24 antigen expression potentiators
WO2002057316A1 (fr) * 2000-12-28 2002-07-25 Kirin Beer Kabushiki Kaisha Nouvel anticorps monoclonal
US7931897B2 (en) 2001-02-07 2011-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hematopoietic tumors
EP3088412B1 (en) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
US20050226869A1 (en) * 2001-10-19 2005-10-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7888478B2 (en) 2002-09-11 2011-02-15 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7858330B2 (en) 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050118163A1 (en) 2002-02-14 2005-06-02 Hidefumi Mizushima Antibody-containing solution pharmaceuticals
US20030223998A1 (en) * 2002-02-27 2003-12-04 Lamb Lawrence S. Targeted immunotherapy of acute lymphoblastic leukemia (ALL)
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
WO2005014651A1 (ja) * 2003-08-11 2005-02-17 Chugai Seiyaku Kabushiki Kaisha 糖鎖改変抗hm1.24抗体
WO2005034994A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 固形腫瘍治療剤
KR101296931B1 (ko) * 2004-10-26 2013-08-14 추가이 세이야쿠 가부시키가이샤 변형된 당쇄를 갖는 항-글리피칸 3 항체
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
US20080299128A1 (en) 2006-06-20 2008-12-04 Myung Kim Effect of Bst2 on inflammation
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
JP5558825B2 (ja) 2007-10-16 2014-07-23 Ｓｂｉバイオテック株式会社 抗ｂｓｔ２抗体
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
US9123149B2 (en) * 2013-03-15 2015-09-01 Columbia Insurance Company Expert color system for color selection with color harmony and color emotion intelligence
CN107619443B (zh) * 2016-07-14 2020-08-14 深圳宾德生物技术有限公司 抗人和鼠cd317的单克隆抗体及其制备方法和应用
CN109748964B (zh) * 2017-11-01 2020-11-17 深圳宾德生物技术有限公司 CD317单链抗体317scFv、其编码序列及制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
AU668349B2 (en) * 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
ZA948016B (en) * 1993-10-15 1995-05-31 Toshio Hirano A membrane protein polypeptide having pre-B cell crowth-supporting ability and a gene thereof
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
AU718463B2 (en) * 1997-02-28 2000-04-13 Chugai Seiyaku Kabushiki Kaisha Inhibitor of lymphocyte activation
US7052873B2 (en) * 1997-10-03 2006-05-30 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
CA2308007C (en) 1997-10-14 2011-05-17 Chugai Seiyaku Kabushiki Kaisha Enhancer for antibody to lymphocytic tumors

Also Published As

Publication number Publication date
IL131381A0 (en) 2001-01-28
UA65561C2 (uk) 2004-04-15
DE69830492T2 (de) 2006-03-16
US6503510B2 (en) 2003-01-07
CN1250381A (zh) 2000-04-12
CA2280875C (en) 2005-07-05
WO1998035698A1 (fr) 1998-08-20
DE69830492D1 (de) 2005-07-14
EP0997152A4 (en) 2001-04-18
TR199901949T2 (xx) 2000-01-21
US20020037288A1 (en) 2002-03-28
CA2280875A1 (en) 1998-08-20
ATE297219T1 (de) 2005-06-15
KR20000070989A (ko) 2000-11-25
ES2241114T3 (es) 2005-10-16
NO993866L (no) 1999-10-11
CN1191855C (zh) 2005-03-09
RU2177805C2 (ru) 2002-01-10
UA65561A (en) 2000-08-15
HUP0001136A3 (en) 2002-02-28
KR100655979B1 (ko) 2006-12-08
PL335140A1 (en) 2000-04-10
PL190065B1 (pl) 2005-10-31
SK110099A3 (en) 2000-08-14
AU724133B2 (en) 2000-09-14
HUP0001136A2 (hu) 2000-08-28
HK1026368A1 (en) 2000-12-15
EP0997152A1 (en) 2000-05-03
KR20030097614A (ko) 2003-12-31
EP0997152B1 (en) 2005-06-08
US20030113334A1 (en) 2003-06-19
BR9811094A (pt) 2000-07-18
AU5956398A (en) 1998-09-08

Similar Documents

Publication Publication Date Title
NO993866D0 (no) Legemiddel mot lymfocytiske tumorer
PT88417A (pt) Stabilisierte humanprotein-praeparate
DK0788509T3 (da) Terapeutiske peptidderivater
CY1110128T1 (el) Καταλυτικα μονοκλωνικα αντισωματα με δραστικοτητα πρωτεασης για την εκλεκτικη λυση του πρωτεϊνικου συστατικου των πλακων και συνονθυλευματων που σχετιζονται με παθολογικες καταστασεις
ATE386808T1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
CY1109881T1 (el) Νεοαγγειακα-συγκεκριμενα πεπτιδια
EP1023906A4 (en) AMPLIFIER FOR ANTIBODY AGAINST LYMPHOIDEN TUMOR
PT983300E (pt) Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.
TH14586A (th) การบำบัดรักษาการเป็นหมัน และเพิ่มความสามารถในการผลิตคิดในสัตว์เลี้ยงลูกด้วยนมตัวผู้